AKRO Akero Therapeutics Inc.

20.29
+0.29  (+1%)
Previous Close 20
Open 20.87
Price To Book 4.51
Market Cap 580,454,555
Shares 28,607,913
Volume 152,122
Short Ratio
Av. Daily Volume 196,407
Stock charts supplied by TradingView

NewsSee all news

  1. venBio Closes $394 Million Life Sciences Venture Capital Fund

    venBio Partners LLC today announced the closing of venBio Global Strategic Fund III ("venBio Fund III"), its third life sciences venture capital fund, exceeding its target and closing on approximately $394 million in

  2. All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study

    SAN FRANCISCO, March 31, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO) today announced that all three AKR-001 dose groups in the BALANCED study met the primary endpoint of absolute change from baseline in

  3. Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001

    SAN FRANCISCO, March 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO) today announced that the company plans to discuss the primary endpoint and other Week 12 efficacy endpoint results from the ongoing

  4. Akero Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

    SAN FRANCISCO, March 16, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) Company developing pioneering medicines designed to restore metabolic balance

  5. Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients

    SAN FRANCISCO, Jan. 13, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a dose groups all met primary endpoint - March 31, 2020. Top-line safety/tolerability, laboratory measures and paired biopsy data due 2Q 2020.
AKR-001
Nonalcoholic steatohepatitis (NASH)

Latest News

  1. venBio Closes $394 Million Life Sciences Venture Capital Fund

    venBio Partners LLC today announced the closing of venBio Global Strategic Fund III ("venBio Fund III"), its third life sciences venture capital fund, exceeding its target and closing on approximately $394 million in

  2. All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study

    SAN FRANCISCO, March 31, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO) today announced that all three AKR-001 dose groups in the BALANCED study met the primary endpoint of absolute change from baseline in

  3. Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001

    SAN FRANCISCO, March 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO) today announced that the company plans to discuss the primary endpoint and other Week 12 efficacy endpoint results from the ongoing

  4. Akero Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

    SAN FRANCISCO, March 16, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) Company developing pioneering medicines designed to restore metabolic balance

  5. Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients

    SAN FRANCISCO, Jan. 13, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

  6. Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 8, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and

  7. Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH

    SAN FRANCISCO, Dec. 16, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

  8. Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

    SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

  9. Akero Therapeutics Reports Recent Highlights and Third Quarter 2019 Financial Results

    SAN FRANCISCO, Nov. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

  10. Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    WARMINSTER, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its third quarter 2019 financial results and

  11. InSphero Wins Sino-European Innovation Award for Breakthrough NASH Discovery and Safety Testing Platform

    SCHLIEREN, Switzerland, Nov. 4, 2019 /PRNewswire/ -- InSphero AG today announced the company received an award at the 2019 Sino-European Innovation Week in Healthcare Technology (SEIWHT) meeting held in Nanjing, China.